Amor Belmeguenai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amor Belmeguenai has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Bezin
Université Claude Bernard Lyon 1, CNRS UMR5292, Inserm U1028, Centre de Recherche en Neurosciences de Lyon, TIGER Team, Bron, France
3 shared publications - Sylvain Rheims
Department of Functional Neurology and Epileptology Hospices Civils de Lyon and Lyon 1 University Lyon France
3 shared publications - Wanda Grabon
Université Claude Bernard Lyon 1, CNRS UMR5292, Inserm U1028, Centre de Recherche en Neurosciences de Lyon, TIGER Team, F-69500 Bron, France
3 shared publications - Anne Ruiz
Lyon 1 Universite, CNRS UMR5292, Inserm U1028, Centre de Recherche en Neurosciences de Lyon, F-69500 Bron, France
2 shared publications Béatrice Georges
Lyon 1 Universite, CNRS UMR5292, Inserm U1028, Centre de Recherche en Neurosciences de Lyon, F-69500 Bron, France
2 shared publications- Jacques Bodennec
Lyon 1 Universite, CNRS UMR5292, Inserm U1028, Centre de Recherche en Neurosciences de Lyon, F-69500 Bron, France
2 shared publications
Latest Publications
- Open Access
CB2 activation during epileptogenesis recruits immunomodulatory monocytes and mitigates cognitive, affective and seizure outcomes
Temporal lobe epilepsy (TLE) is frequently associated with severe cognitive impairment and psychiatric comorbidities that are highly disabling and not targeted by anti-seizure medications, highlighting the need for therapies that target epileptogenesis rather than merely suppress seizures. Despite strong evidence implicating neuroinflammation in this process, anti-inflammatory approaches have not yielded such therapies yet. Infiltrating peripheral monocytes are widely viewed as detrimental amplifiers of post–status epilepticus (SE) inflammation, although emerging data suggest context-dependent protective roles. The cannabinoid receptor type 2 (CB2), highly expressed in myeloid cells, represents a potential immunomodulatory target linking leukocyte recruitment and inflammatory polarization. Using a juvenile rat model of TLE, we characterized hippocampal neuroinflammation and CB2 expression during epileptogenesis and evaluated the effects of transient CB2 activation with the selective agonist GP1a. SE induced a rapid but transient inflammatory response and robust recruitment of peripheral monocytes that persisted as anti-inflammatory monocyte-derived macrophages. CB2 activation did not suppress early cytokine induction but selectively enhanced recruitment of anti-inflammatory monocytes and modestly increased anti-inflammatory signaling. Importantly, transient CB2 stimulation preserved synaptic plasticity, improved cognitive performance, reduced anxiety-like behavior, and delayed seizure onset. These findings identify CB2-dependent modulation of peripheral myeloid cells as a potential disease-modifying axis in TLE.
Open AccessCB2 activation during epileptogenesis recruits immunomodulatory monocytes and mitigates cognitive, affective and seizure outcomes
Temporal lobe epilepsy (TLE) is frequently associated with severe cognitive impairment and psychiatric comorbidities that are highly disabling and not targeted by anti-seizure medications, highlighting the need for therapies that target epileptogenesis rather than merely suppress seizures. Despite strong evidence implicating neuroinflammation in this process, anti-inflammatory approaches have not yielded such therapies yet. Infiltrating peripheral monocytes are widely viewed as detrimental amplifiers of post–status epilepticus (SE) inflammation, although emerging data suggest context-dependent protective roles. The cannabinoid receptor type 2 (CB2), highly expressed in myeloid cells, represents a potential immunomodulatory target linking leukocyte recruitment and inflammatory polarization. Using a juvenile rat model of TLE, we characterized hippocampal neuroinflammation and CB2 expression during epileptogenesis and evaluated the effects of transient CB2 activation with the selective agonist GP1a. SE induced a rapid but transient inflammatory response and robust recruitment of peripheral monocytes that persisted as anti-inflammatory monocyte-derived macrophages. CB2 activation did not suppress early cytokine induction but selectively enhanced recruitment of anti-inflammatory monocytes and modestly increased anti-inflammatory signaling. Importantly, transient CB2 stimulation preserved synaptic plasticity, improved cognitive performance, reduced anxiety-like behavior, and delayed seizure onset. These findings identify CB2-dependent modulation of peripheral myeloid cells as a potential disease-modifying axis in TLE.
- Open Access
Cannabinoid receptor type 2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions
Since its detection in the brain, the cannabinoid receptor type 2 (CB2) has been deemed a promising therapeutic target for various neurological and psychiatric disorders. However, precise brain mapping of CB2 expression is currently lacking. Using magnetic cell sorting, calibrated reverse transcription-quantitative PCR, and single-nucleus RNA-seq, we revealed the low level of CB2 expression in all brain regions examined, mainly by a few microglial cells and by neurons in an even lower proportion. Upon lipopolysaccharide stimulation to simulate non-sterile neuroinflammatory conditions, we demonstrated that the inflammatory response was associated with a transient reduction in CB2 mRNA levels in the brain tissue, particularly in microglia. This result, confirmed in the BV2 microglial cells, contrasts with the positive correlation observed between CB2 mRNA levels and the inflammatory response upon stimulation by interferon-gamma, which models sterile inflammatory conditions. Thus, discrete brain CB2 expression may be upregulated or downregulated depending on the inflammatory context.
Open AccessCannabinoid receptor type 2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions
Since its detection in the brain, the cannabinoid receptor type 2 (CB2) has been deemed a promising therapeutic target for various neurological and psychiatric disorders. However, precise brain mapping of CB2 expression is currently lacking. Using magnetic cell sorting, calibrated reverse transcription-quantitative PCR, and single-nucleus RNA-seq, we revealed the low level of CB2 expression in all brain regions examined, mainly by a few microglial cells and by neurons in an even lower proportion. Upon lipopolysaccharide stimulation to simulate non-sterile neuroinflammatory conditions, we demonstrated that the inflammatory response was associated with a transient reduction in CB2 mRNA levels in the brain tissue, particularly in microglia. This result, confirmed in the BV2 microglial cells, contrasts with the positive correlation observed between CB2 mRNA levels and the inflammatory response upon stimulation by interferon-gamma, which models sterile inflammatory conditions. Thus, discrete brain CB2 expression may be upregulated or downregulated depending on the inflammatory context.
- Open Access
- 5 January 2023
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 29 (3) , 760-770
Update on the controversial identity of cells expressing cnr2 gene in the nervous system
The function of cannabinoid receptor type 2 (CB2R), mainly expressed by leukocytes, has long been limited to its peripheral immunomodulatory role. However, the use of CB2R‐specific ligands and the availability of CB2R‐Knock Out mice revealed that it could play a functional role in the CNS not only under physiological but also under pathological conditions. A direct effect on the nervous system emerged when CB2R mRNA was detected in neural tissues. However, accurate mapping of CB2R protein expression in the nervous system is still lacking, partly because of the lack of specificity of antibodies available. This review examines the regions and cells of the nervous system where CB2R protein is most likely present by cross‐referencing mRNA and protein data published to date. Of the many antibodies developed to target CB2R, only a few have partially passed specificity tests and detected CB2R in the CNS. Efforts must be continued to support the development of more specific and better validated antibodies in each of the species in which CB2R protein is sought or needs to be quantified.
- 5 January 2023
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 29 (3) , 760-770
Open AccessUpdate on the controversial identity of cells expressing cnr2 gene in the nervous system
The function of cannabinoid receptor type 2 (CB2R), mainly expressed by leukocytes, has long been limited to its peripheral immunomodulatory role. However, the use of CB2R‐specific ligands and the availability of CB2R‐Knock Out mice revealed that it could play a functional role in the CNS not only under physiological but also under pathological conditions. A direct effect on the nervous system emerged when CB2R mRNA was detected in neural tissues. However, accurate mapping of CB2R protein expression in the nervous system is still lacking, partly because of the lack of specificity of antibodies available. This review examines the regions and cells of the nervous system where CB2R protein is most likely present by cross‐referencing mRNA and protein data published to date. Of the many antibodies developed to target CB2R, only a few have partially passed specificity tests and detected CB2R in the CNS. Efforts must be continued to support the development of more specific and better validated antibodies in each of the species in which CB2R protein is sought or needs to be quantified.